文献速递中医内科中药与中成药合理使用中医儿科

中草药治疗急性感染性疾病的临床证据:系统评价综述

Clinical Evidence on the Use of Chinese Herbal Medicine for Acute Infectious Diseases: An Overview of Systematic Reviews.
PubMed 文献 · Front Pharmacol · 2022-02-25

该综述检索多个数据库,纳入51篇关于中草药治疗急性感染性疾病的系统评价/Meta分析,涵盖COVID-19、手足口病、SARS等。AMSTAR 2质量评估显示6篇高质量(均为COVID-19),24篇中等,10篇低,11篇极低。中草药可能改善多数感染的症状与体征且安全性可接受,对COVID-19、SARS和H1N1等急性呼吸道感染的证据较其他感染更充分。

要点

  • 中草药单用或联合常规西药可能缓解急性呼吸道感染症状。
  • 纳入的51篇系统评价中仅6篇方法学高质量,均关于COVID-19。
  • 未来研究应聚焦呼吸道感染的单用(轻症)与辅助(重症)及个体化处方。

核心结论

  • 中草药(汤剂和中成药)单用或联合常规药物可能对缓解急性呼吸道感染患者症状有潜在益处。

研究设计与样本

  • 检索CBM、CNKI、万方、PubMed、Cochrane Library、Embase及预印本平台,纳入51篇关于中草药治疗急性感染性疾病的系统评价/Meta分析。

主要发现

  • 51篇系统评价中,COVID-19有19篇,手足口病11篇,SARS 8篇,结核4篇,流行性腮腺炎3篇,细菌性痢疾2篇,H1N1流感2篇,疱疹性咽峡炎2篇。
  • 方法学质量:6篇高质量(均为COVID-19),24篇中等,10篇低,11篇极低。
  • 中草药对多数感染在改善临床症状和体征方面显示潜在获益,且安全性可接受。
  • COVID-19、SARS和H1N1等急性呼吸道感染的临床证据较其他急性感染更充分。

临床怎么用

  • 可考虑将中草药(汤剂或中成药)单用或联合常规西药用于缓解急性呼吸道感染症状。
  • 应用时需关注所依据系统评价的方法学质量,高质量证据仅限COVID-19。

局限性

  • 多数纳入系统评价方法学质量不高(仅6篇高质量)。
  • 疾病分型、分期、严重程度及干预细节报告不完整,影响证据转化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Acute infectious diseases constitute the most prevalent public health emergency (PHE) in China. Chinese herbal medicine (CHM) has long been used in the treatment of acute infections, but the overall evidence of its benefit and harm has not been comprehensively and systematically evaluated. Methods: We searched CBM, CNKI, Wanfang, PubMed, Cochrane Library, embase and preprint platforms to retrieve systematic reviews (SRs) on CHM for acute infectious. Participants with COVID-19, SARS, H1N1, tuberculosis, bacillary dysentery, mumps, herpangina, hand-foot-and-mouth disease (HFMD), and other acute infectious diseases were included. Interventional group consisting of patients treated with CHM combined with Western medicine or CHM alone. The AMSTAR 2 tool was used to assess the methodological quality of the retrieved studies. Information on interventions, control measures and outcomes of the included studies was extracted, and meta-analyses were qualitatively synthesized. Results: A total of 51 SRs and meta-analyses were eligible for this overview, including 19 for COVID-19, 11 for hand-foot-and-mouth disease, 8 for severe acute respiratory syndrome (SARS), 4 for tuberculosis, 3 for mumps, 2 for bacillary dysentery, 2 for H1N1 influenza and 2 for herpangina. Six systematic reviews were of high quality, all of which were on the use of CHM for COVID-19; 24 were of moderate quality; 10 were of low quality; and 11 were of very low quality. CHM appeared to have potential benefits in improving clinical symptoms and signs for most infections with an acceptable safety profile, and the clinical evidence of the benefits of CHM for acute respiratory infections such as COVID-19, SARS and H1N1 seems more sufficient than that for other acute infections. Conclusion: Overall, CHM, both decoction and Chinese patent medicine, used alone or in combination with conventional medicine may offer potential benefits to relieving symptoms of people with acute respiratory infections. Full reporting of disease typing, staging, and severity, and intervention details is further required for a better evidence translation to the responses for PHE. Future CHM research should focus mainly on the specific aspects of respiratory infections such as its single use for mild infections, and the adjunct administration for sever infections, and individual CHM prescriptions for well-selected outcomes should be prioritized.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Luo X, Zhang Y, Li H, et al. Clinical Evidence on the Use of Chinese Herbal Medicine for Acute Infectious Diseases: An Overview of Systematic Reviews. Front Pharmacol. 2022. PMID: 35281902. doi:10.3389/fphar.2022.752978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。